Back to Journals » Journal of Pain Research » Volume 3

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

Authors Recla J

Published 22 July 2010 Volume 2010:3 Pages 89—103

DOI https://doi.org/10.2147/JPR.S6792

Review by Single anonymous peer review

Peer reviewer comments 5



Jill M Recla

IGERT Program in Functional Genomics, Graduate School of Biomedical Sciences, University of Maine and The Jackson Laboratory, Bar Harbor, Maine, USA

Abstract: Fibromyalgia (FM) is a chronic widespread pain condition that is estimated to affect
5 million US adults. Several molecular pathophysiologies are thought to contribute to the symptoms of FM, complicating the development of effective clinical management techniques. It is now known that abnormalities in both nociceptive and central pain processing systems are necessary (but perhaps not sufficient) to condition the onset and maintenance of FM, producing associated neuropsychologic symptoms such as pronounced fatigue, sleep abnormalities, cognitive difficulties, stress sensitivity, anxiety, and depression. Current treatment strategies are focused primarily on correcting the pathophysiologic mechanisms underlying these nervous system abnormalities. Clinical studies demonstrate the safety and efficacy of three drugs recently approved for the treatment of FM: pregabalin (an alpha-2-delta ligand), and duloxetine and milnacipran (serotonin/norepinephrine reuptake inhibitors). This review describes these pharmaceuticals in detail and discusses their current roles in FM management.

Keywords: fibromyalgia, treatment, pharmacotherapy, pregabalin, duloxetine, milnacipran

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.